Mobile

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients who Were Null or Partial Responders to ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001180-53

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the non-inferiority of TMC435 versus TVR, both given in combination with PegIFNα-2a and RBV, by less than 12%, with respect to the proportion of subjects with SVR 12 weeks after the planned end of treatment (SVR12).

Critère d'inclusion

  • Hepatitis C Virus (HCV) genotype-1 infection

Liens